CellSource Co., Ltd.
CellSource FY2026 Earnings Forecast and Transition to Non-Consolidated Financial Statements | July 29, 2026
CellSource will transition to non-consolidated accounting beginning from the third quarter of FY2026 (October 2025 quarter), recording a special profit of 65 million yen related to absorption merger. The forecast for FY2026 individual sales is 3,320 million yen, with a net loss of △107 million yen.
Key Figures
- Sales: 3,320 million yen (FY2026 individual forecast)
- Net income: △107 million yen (FY2026 individual forecast)
- Absorption merger extinguishment gains: 65 million yen
AI要約
Financial Results Overview
CellSource merged with Hybrid Medical Inc. on July 1, 2026, resulting in no consolidated subsidiaries, and transitioned to non-consolidated financial statements from the third quarter of FY2026. During this transition, a special profit of 65 million yen related to absorption merger extinguishment gains was recognized. The FY2026 individual earnings forecast projects sales of 3,320 million yen, operating loss of △221 million yen, ordinary loss of △210 million yen, and net loss of △107 million yen.
Future Outlook and Impact on Shareholders
The FY2026 earnings forecast reflects the transition to non-consolidated financial statements and the impact of the merger, with a projected net loss. The outlook is currently under detailed review and may be revised. Investors should pay attention to the structural changes caused by non-consolidation and the merger.
セルソース株式会社
Company overview · Stock price · Financial data · All IR
